Abstract
Surgery in metastatic gastric cancer may be sometimes required when oligometastatic patients are confirmed at re-staging after neoadjuvant treatment, or when palliative chemotherapy makes it possible allow to remove previously unresectable cancer. This second approach, defined as conversion surgery, has better results in comparison to simple oncologic treatment not only in liver metastases but also in patients with lymphatic metastases or carcinosis. Complete R0 resection is regarded as a significant prognostic factor also in conversion surgery, but in these patients the R0 resection must only consider the residual disease and not the initial volume. New oncologic drugs are proposed and the survival rates reported in the literature are promising; however, collaboration within a multidisciplinary team is the key point for this stage of the disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2012. Toronto, ON: Canadian Cancer Society; 2012. p. 67.
McGhan LJ, Pockaj BA, Gray RJ, et al. Validation of the updated 7th edition AJCC TNM staging criteria for gastric adenocarcinoma. J Gastrointest Surg. 2012;16(1):53–61.
Coburn NG, Lourenco LG, Rossi SE, et al. Management of gastric cancer in Ontario. J Surg Oncol. 2010;102(1):54–63.
An JY, Ha TK, Noh JH, et al. Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009;144(1):38–45.
Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.
Kodera Y, Fujitani K, Fukushima N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17(2):206–12.
Komeda K, Hayashi M, Kubo S, et al. High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study. World J Surg. 2014;38(10):2692–7.
Tiberio GA, Baiocchi GL, Morgagni P, et al. Gastric cancer and synchronous hepatic metastases: is it possible to recognize candidates to R0 resection? Ann Surg Oncol. 2015;22(2):589–96.
Ministrini S, Solaini L, Cipollari C, et al. Surgical treatment of hepatic metastases from gastric cancer. Updat Surg. 2018;70(2):273–8.
Tiberio GA, Ministrini S, Gardini A, et al. Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol. 2016;42(8):1229–35.
Ministrini S, Bencivenga M, Solaini L, et al. Stage IV gastric cancer. The surgical perspective of the Italian Research Group on Gastric Cancer. Cancers (Basel). 2020;12(1):158. https://doi.org/10.3390/cancers12010158.
Izuishi K, Haba R, Kushida Y, et al. S-1 and the treatment of gastric cancer with peritoneal dissemination. Exp Ther Med. 2011;2(5):985–90.
Fava BEC, da Costa WL Jr, Medeiros MLL, et al. Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a Western single center. World J Surg Oncol. 2018;16(1):62. https://doi.org/10.1186/s12957-018-1363-0.
Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329–38.
Terashima M, Yoshida K, Rha SY, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). J Clin Oncol. 2018;36(15 Suppl):4042.
Hayano K, Watanabe H, Ryuzaki T, et al. Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy. Surg Case Rep. 2020;6(1):219. https://doi.org/10.1186/s40792-020-00984-w.
Matsumoto R, Arigami T, Matsushita D, et al. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol. 2020;18(1):179. https://doi.org/10.1186/s12957-020-01954-0.
Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–7.
Acknowledgments
Special thanks are extended to Silvia Ministrini, Leonardo Solaini, Chiara Cipollari, Silvia Sofia, Elisabetta Marino, Alessia d’Ignazio, Beatrice Molteni, Gianni Mura, Luigina Graziosi for their contribution and support, in particular for investigation, bibliography resources, and review.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Morgagni, P., Bencivenga, M., Tiberio, G.A.M. (2022). Surgery for Stage IV Gastric Cancer: The New Edge. In: de Manzoni, G., Roviello, F. (eds) Gastric Cancer: the 25-year R-Evolution. Updates in Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-73158-8_21
Download citation
DOI: https://doi.org/10.1007/978-3-030-73158-8_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-73157-1
Online ISBN: 978-3-030-73158-8
eBook Packages: MedicineMedicine (R0)